NCT03445533 2022-11-08
A Study of Tilsotolimod in Combo With Ipilimumab vs Ipilimumab Alone in Subjects With Anti-PD-1 Refractory Melanoma
Idera Pharmaceuticals, Inc.
Phase 3 Terminated
Idera Pharmaceuticals, Inc.
Idera Pharmaceuticals, Inc.
Idera Pharmaceuticals, Inc.